From the dawn of Crispr in 2012, medical scientists have recognized the gene-editing tool’s potential to treat, or even cure, genetic diseases.
New data from Intellia Therapeutics is making their hopes more realistic than ever. The company’s Crispr therapy was able to significantly lower patients’ levels of a misfolded liver protein and keep them low for months.
This comes as very good news for many biotech companies racing to develop therapies that stop the human liver from making bad-behaving proteins.
The Nobel prize-winning Crispr technology is moving from concept to clinic at breathtaking pace. Intellia is the first company to demonstrate success in so-called “in vivo” editing — that is, in living human cells. (The field has also seen some early good results in “ex vivo” editing, where cells are removed from the body, edited in a lab and then given back to a patient.)
Intellia’s data came from a phase 1 trial of a therapy it is developing with Regeneron Pharmaceuticals that reduces output of the protein transthyretin, or TTR. In people with TTR amyloidosis, the liver makes a misfolded version of this protein, which then clumps together and builds up, causing damage to organs and nerves.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.